+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Alpha V Beta 5 Integrin Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha V Beta 5 Integrin Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Endothelin Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Endothelin Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
D1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

D1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
PPAR-Beta / Delta Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

PPAR-Beta / Delta Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT2C Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2C Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
D2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

D2 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Delayed Cerebral Ischaemia (DCI) - Pipeline Insight, 2025 - Product Thumbnail Image

Delayed Cerebral Ischaemia (DCI) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Alternating Hemiplegia Of Childhood (AHC) - Pipeline Insight, 2025 - Product Thumbnail Image

Alternating Hemiplegia Of Childhood (AHC) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Neuroendocrine Tumours - Pipeline Insight, 2025 - Product Thumbnail Image

Neuroendocrine Tumours - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
mGlu5 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

mGlu5 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Primary Mitochondrial Myopathies - Pipeline Insight, 2025 - Product Thumbnail Image

Primary Mitochondrial Myopathies - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Somatostatinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Somatostatinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
CLN1 - Pipeline Insight, 2025 - Product Thumbnail Image

CLN1 - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Hearing Loss- Pipeline Insight, 2025 - Product Thumbnail Image

Hearing Loss- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 150 Pages
  • Global
From
Kabuki Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Kabuki Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
MOG Antibody Disease - Pipeline Insight, 2025 - Product Thumbnail Image

MOG Antibody Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Circadian Rhythm Disorders - Pipeline Insight, 2025 - Product Thumbnail Image

Circadian Rhythm Disorders - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Motor Neuron Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Motor Neuron Disease- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 450 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more